Showing results (1751-1760 of 2,138) with videos related to

Sort By:
Pageof 214
Archives of Ophthalmology (Chicago, Ill. : 1960)|February 1, 1996
Linkage of autosomal dominant radial drusen (malattia leventinese) to chromosome 2p16-21E Héon, B Piguet, F Munier, et al.
Leukemia & Lymphoma|October 26, 2022
Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitorsJan Philipp Bewersdorf, Rory M Shallis, Andriy Derkach, et al.
Cancer|June 30, 2012
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802Wendy Stock, Jeffrey L Johnson, Richard M Stone, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|February 15, 2018
Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosisGemma Modinos, Fatma Şimşek, Matilda Azis, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|October 23, 2009
Visual impairment in the absence of dystroglycanJakob S Satz, Alisdair R Philp, Huy Nguyen, et al.
Blood Advances|December 12, 2022
Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemiaShai Shimony, Yiwen Liu, Yannis K Valtis, et al.
Plos One|May 17, 2018
Integrative omics to detect bacteremia in patients with febrile neutropeniaRachel S Kelly, Jessica Lasky-Su, Sai-Ching J Yeung, et al.
Biomacromolecules|July 26, 2018
Effect of Molecular Weight and Functionality on Acrylated Poly(caprolactone) for Stereolithography and Biomedical ApplicationsBrian J Green, Kristan S Worthington, Jessica R Thompson, et al.
Iscience|September 26, 2022
Coxsackievirus B infections are common in Cystic Fibrosis and experimental evidence supports protection by vaccinationVirginia M Stone, Renata Utorova, Marta Butrym, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2008
Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720Maria R Baer, Stephen L George, Michael A Caligiuri, et al.
Pageof 214